Humoral Response Dynamics Following Infection with SARS-CoV-2

Objectives To understand humoral dynamics following SARS-CoV-2 infection Design Prospective Cohort Study Setting Great Ormond Street Hospital (Central London Paediatric Hospital) Participants 67 healthcare workers aged >18 years who provided monthly serial serological samples from 29th April 2020 until 30th June 2020. Main outcome measures The change in monthly serial antibody titers to SARS-CoV-2 nucleoprotein (N), spike protein and the receptor binding domain of the spike protein. Results The mean estimated half-life of the nucleoprotein antibody was 52 days (95% CI 42-65). The spike and RBD antibody had significantly longer mean half-lives of 81 days (95% CI 61-111) and 83 days (95% CI 55-137) respectively. An ACE-2 receptor competition assay demonstrated significant correlation between the spike and RBD antibody titers and ACE2 receptor blocking in-vitro. The time to a negative nucleoprotein antibody test for 50% of the seropositive population was predicted to be 195 days (95% CI 163-236). Conclusions After SARS-CoV-2 infection, the predicted half-life of nucleoprotein antibody was 52 days with 50% of seropositives becoming seronegative to this antibody at 195 days. Widely used serological tests including the Public Health England endorsed assay that depend on the nucleoprotein antibody will therefore underestimate the true prevalence of infection within a year following the majority of infections.

[1]  A. A. Ano Bom,et al.  Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection? , 2020, Cellular Immunology.

[2]  M. Lipsitch,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[3]  Vineet D. Menachery,et al.  Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients , 2020, Cell Reports Medicine.

[4]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[5]  E. Fischer,et al.  Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2 , 2020, bioRxiv.

[6]  D. Tyrrell,et al.  The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.

[7]  C. Whittaker,et al.  Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.

[8]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[9]  Diana Boraschi,et al.  Immunosenescence and vaccine failure in the elderly: strategies for improving response. , 2014, Immunology letters.

[10]  C. Siegrist,et al.  B-cell responses to vaccination at the extremes of age , 2009, Nature Reviews Immunology.

[11]  Yonatan H. Grad,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[12]  P. Kellam,et al.  The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection , 2020, The Journal of general virology.

[13]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[14]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[15]  M. Ulaşlı,et al.  Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle , 2019, Journal of Virology.

[16]  Nicholas C. Wu,et al.  Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections , 2020, bioRxiv.

[17]  S. Perlman,et al.  Antibody Response and Disease Severity in Healthcare Worker MERS Survivors , 2016, Emerging infectious diseases.

[18]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[19]  Vineet D. Menachery,et al.  Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients , 2020, Cell Reports Medicine.

[20]  P. Sopp,et al.  Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients , 2020, bioRxiv.

[21]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[22]  Ewen Callaway,et al.  The race for coronavirus vaccines: a graphical guide , 2020, Nature.

[23]  C. Hillyer,et al.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.

[24]  M. Chen,et al.  A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction , 2020 .

[25]  Kyoung-Ho Song,et al.  MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015 , 2017, Emerging infectious diseases.

[26]  Chuan Qin,et al.  Reinfection could not occur in SARS-CoV-2 infected rhesus macaques , 2020 .

[27]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[28]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[29]  Jérôme Hugues,et al.  Model‐Based Analysis , 2013 .

[30]  Jeng-Min Chiou,et al.  Neutralizing Antibody Response and SARS Severity , 2005, Emerging infectious diseases.

[31]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[32]  A. Tamin,et al.  Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus , 2016, Emerging infectious diseases.

[33]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[34]  Quanyi Wang,et al.  Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients , 2020, medRxiv.

[35]  Tingmei Wang,et al.  Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 , 2020, Clinical & translational immunology.

[36]  A. Handel,et al.  Heterogeneity and longevity of antibody memory to viruses and vaccines , 2018, PLoS biology.

[37]  W. Cao,et al.  Disappearance of antibodies to SARS-associated coronavirus after recovery. , 2007, The New England journal of medicine.

[38]  Lin‐Fa Wang,et al.  Duration of Antibody Responses after Severe Acute Respiratory Syndrome , 2007, Emerging infectious diseases.

[39]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[40]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[41]  D. Cummings,et al.  A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease , 2020, medRxiv.

[42]  F. Crauste,et al.  A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus. , 2020, Journal of theoretical biology.

[43]  Xinquan Wang,et al.  Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.